Drug Profile
MBL HCV1
Alternative Names: MBL-HCV1Latest Information Update: 03 Mar 2016
Price :
$50
*
At a glance
- Originator MassBiologics
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis C virus envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 19 Feb 2016 MassBiologics terminates a phase II trial in Hepatitis C in USA (NCT01121185)
- 12 Feb 2016 MassBiologics terminates phase II trial in Hepatitis C in the US (NCT01532908)
- 14 Sep 2015 Phase-II development for Hepatitis C is ongoing in USA